Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244522 | 1.00 | MAPT (0.52) | MAPTHPGDLMNACRHBPMAPK1 | |
| SCHEMBL337773 | 1.00 | MAPT (0.52) | MAPTHPGDLMNACRHBPMAPK1 | |
| SCHEMBL8248506 | 1.00 | MAPT (0.52) | MAPTHPGDLMNACRHBPMAPK1 | |
| SCHEMBL13759541 | 1.00 | MAPT (0.52) | MAPTHPGDLMNACRHBPMAPK1 | |
| SCHEMBL3773115 | 1.00 | MAPT (0.52) | MAPTHPGDLMNACRHBPMAPK1 | |
| SCHEMBL17298642 | 0.90 | MAPT (0.51) | MAPTHPGDLMNACRHBPMAPK1 | |
| SCHEMBL11931666 | 0.89 | MAPT (0.50) | MAPTHPGDLMNACRHBPMAPK1 | |
| SCHEMBL6881780 | 0.89 | MAPT (0.50) | MAPTHPGDLMNACRHBPMAPK1 | |
| SCHEMBL337989 | 0.89 | MAPT (0.50) | MAPTHPGDLMNACRHBPMAPK1 | |
| SCHEMBL2013099 | 0.87 | MAPT (0.51) | MAPTHPGDLMNACRHBPMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2916832-B1 | A PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LTD (IN) | 2019-01-16 | — | — | EP | disclosed |
| US-10023885-B2 | Process for the preparation of pregabalin | HIKAL LIMITED (IN) | 2018-07-17 | — | — | US | disclosed |
| US-10023885-B2 | Process for the preparation of pregabalin | HIKAL LIMITED (IN) | 2018-07-17 | — | — | US | disclosed |
| US-20150344919-A1 | PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LIMITED (IN) | 2015-12-03 | — | — | US | disclosed |
| US-20150344919-A1 | PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LIMITED (IN) | 2015-12-03 | — | — | US | disclosed |
| WO-2014072785-A2 | A PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LIMITED (IN) | 2014-05-15 | — | — | WO | disclosed |
| US-7563923-B2 | Prepared by decyclization and amidation of 3-isobutylglutaric anhydride with chiral 1-amino-1-arylalkane by dissolving amine in aromatic hydrocarbon, ether, halogenated hydrocarbon, alcohol, ester, alkane, or ketone solvent; cooling to +10 to -70 degrees C.; and reacting with anhydride | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-21 | — | — | US | disclosed |
| US-7563923-B2 | Prepared by decyclization and amidation of 3-isobutylglutaric anhydride with chiral 1-amino-1-arylalkane by dissolving amine in aromatic hydrocarbon, ether, halogenated hydrocarbon, alcohol, ester, alkane, or ketone solvent; cooling to +10 to -70 degrees C.; and reacting with anhydride | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-21 | — | — | US | disclosed |
| US-7563923-B2 | Prepared by decyclization and amidation of 3-isobutylglutaric anhydride with chiral 1-amino-1-arylalkane by dissolving amine in aromatic hydrocarbon, ether, halogenated hydrocarbon, alcohol, ester, alkane, or ketone solvent; cooling to +10 to -70 degrees C.; and reacting with anhydride | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-21 | — | — | US | disclosed |
| US-7470812-B2 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-30 | — | — | US | disclosed |
| US-7465826-B2 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-16 | — | — | US | disclosed |
| CN-101282924-A | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (S)-pregabalin | TEVA PHARMA (IL) | 2008-10-08 | — | — | CN | disclosed |
| US-20080051602-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | KANSAL VINOD K | 2008-02-28 | — | — | US | disclosed |
| US-20080051602-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | KANSAL VINOD K | 2008-02-28 | — | — | US | disclosed |
| US-20080045747-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | KANSAL VINOD K | 2008-02-21 | — | — | US | disclosed |
| US-20080045747-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | KANSAL VINOD K | 2008-02-21 | — | — | US | disclosed |
| US-20070191636-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | TEVA PHARMACEUTICAL USA, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191636-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | TEVA PHARMACEUTICAL USA, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1802568-A1 | CHIRAL 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACIDS, KEY INTERMEDIATES FOR THE NEW SYNTHESIS OF (S)-PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007035789-A1 | CHIRAL 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACIDS, KEY INTERMEDIATES FOR THE NEW SYNTHESIS OF (S)-PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045747-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | GABRE, GABRA5, GABRA6 | MAPT 1546/4885HPGD 1571/4885LMNA 4132/4885 |
| US-10023885-B2 | Process for the preparation of pregabalin | CHRNA6, CHRNA9, ADH5 | MAPT 2852/4885HPGD 199/4885LMNA 1468/4885 |
| US-20080051602-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | GABRE, GABRA5, GABRA6 | MAPT 1546/4885HPGD 1571/4885LMNA 4132/4885 |
| US-20070191636-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | GABRE, GABRA5, GABRA6 | MAPT 1546/4885HPGD 1571/4885LMNA 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.